Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Our volunteers generously give us their time, skills and experience to tell people about our work, and to help us raise vital funds for research into better treatments and ultimately a cure for T1D.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & Events > Media centre
Are you a journalist seeking information about type 1 diabetes and our mission to prevent, treat and cure the condition? We are able to provide members of the media with:
For all media enquiries in the UK please email pressoffice@breakthrought1d.org.uk. This email is monitored between 09:00 and 17:30 Monday to Friday.
Please note: the above email address is for enquiries from the media/journalists only. Please email info@breakthrought1d.org.uk with all other enquiries.
For all enquiries in the US please email media@BreakthroughT1D.org.
Breakthrough T1D is supporting a major new call to action urging Government and the sport and physical activity sector to remove barriers faced by people living with diabetes.
New research suggests that B cells play a major role in damaging protective immune cells called Tregs. Protecting Tregs could help protect insulin-producing cells in the early stages of T1D.
We're delighted to announce a £350,000 donation from the Bukhman Foundation to support our Community Engagement programme.
A major UK study has shown that screening children for type 1 diabetes (T1D) can identify the condition in its earliest stages, before symptoms appear, offering families time, choices, and hope.
The European Commission has approved Teizeild, the European brand name for the immunotherapy teplizumab, for use in people with stage 2 type 1 diabetes (T1D). This marks an important step forward in efforts to delay the progression of the condition.
Highlights from an extraordinary year in type 1 diabetes (T1D) research, treatment, advocacy and policy.
Breakthrough T1D has been made aware of a product update issued by Abbott for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors. Some sensors have been providing incorrect low glucose readings.
The Bukhman Foundation has donated the money to establish the Bukhman Centre for Research Excellence in Type 1 Diabetes.
